Good practice statements for antithrombotic therapy in the management of COVID‐19: Guidance from the SSC of the ISTH

Despite the emergence of high quality randomized trial data with the use of antithrombotic agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in patients with coronavirus disease 2019 (COVID‐19), questions still remain as to optimal patient selection for these st...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of thrombosis and haemostasis Vol. 20; no. 10; pp. 2226 - 2236
Main Authors:	Spyropoulos, Alex C., Connors, Jean M., Douketis, James D., Goldin, Mark, Hunt, Beverley J., Kotila, Taiwo R., Lopes, Renato D., Schulman, Sam, the International Society on Thrombosis and Haemostasis
Format:	Journal Article
Language:	English
Published:	England Elsevier Inc 01.10.2022 Elsevier Limited John Wiley and Sons Inc
Subjects:	anticoagulant Anticoagulants - therapeutic use antiplatelet Antiplatelet therapy antithrombotic therapy coronavirus disease 2019 Coronaviruses COVID-19 COVID-19 Drug Treatment Critical care Fibrinolytic Agents - therapeutic use Hemostasis hospitalization Humans Patients Platelet Aggregation Inhibitors - therapeutic use Recommendations and Guidelines severe acute respiratory syndrome coronavirus 2 Thromboembolism Thrombosis Thrombosis - drug therapy Thrombosis - prevention & control Venous Thromboembolism - prevention & control anticoagulant antithrombotic therapy hospitalization severe acute respiratory syndrome coronavirus 2 antiplatelet coronavirus disease 2019
ISSN:	1538-7836, 1538-7933, 1538-7836
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!